Fernand Labrie

Publications

Page 1 of 8, showing 50 records out of 362 total, starting on record 1, ending on 50

Publication Category Year
362. Samson, M., Labrie, F., Zouboulis, C.C., Luu-The, V. (2010) Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as intermediate in the SZ95 sebaceous gland cell line. J Invest Derm. 130:602-604 Prostate Cancer 2010
361. Samson, M., Labrie, F., Luu-The, V. (2010) Sequential transformation of 4-androstenedione into dihydrotestosterone in prostate carcinoma (DU-145) cells indicates that 4-androstenedione and not testosterone is the substrate of 5alpha-reductase. Horm Mol Clin Invest. 1: 67-72. Prostate Cancer 2010
360. Labrie, F. (2010) Hormonal therapy of prostate cancer. In: Martini L, Chrousos GP, Labrie F, Pacak K, Pfaff De, eds. Pathological Situations and Diseases, Progress in Brain Research. Elsevier. Chapter 14, Vol. 182 321-341. Prostate Cancer 2010
359. Bydal, P., Luu-The, V., Labrie, F., Poirier, D. (2009) Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: Chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem.44:632-644. Prostate Cancer 2009
358. Spitz, I.M., Chertin, B., Fridmans, A., Farkas, A., Bélanger, A., Hartman, H., Labrie, F. (2009). Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. Prostate Cancer Prostatic Dis, 12: 100-103. Prostate Cancer 2009
357. Labrie, F., Cusan, L., Gomez, J.L., Martel, C., Bérubé, R., Bélanger, P., Bélanger, A., Vandenput, L., Mellström, D., Ohlsson, C. (2009) Comparable Amounts of Sex Steroids are Made Outside the Gonads in Men and Women: Strong Lesson for Hormone Therapy of Prostate and Breast Cancer, JSBMB, 113: 52-56. Prostate Cancer 2009
356. Ma, C., Yoshioka, M., Boivin, A., Gan, L, Takase, Y, Labrie, F., St-Amand, J. (2009) Atlas of dihydrotestosterone actions on the transcriptome of prostate in vivo. The Prostate, 69: 293-316 Prostate Cancer 2009
355. Lévesque, M.H., El-Alfy, M., Cusan, L., Labrie, F. (2009) Androgen receptor as a potential sign of prostate cancer metastasis, The Prostate, 69: 1704-1711. Prostate Cancer 2009
354. Labrie, F. (2008) Preface. Best Pract Res Clin Endocrinol Metab, 22: pp. vii-ix. Prostate Cancer 2008
353. Luu-The, V., Bélanger, A., Labrie, F. (2008) Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab, 22: 207-221. Prostate Cancer 2008
352. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 241-254. Prostate Cancer 2008
351. Labrie, F., Koutsilieris, M. (2008) The 12th International Congress on Hormonal Steroids and Hormones & Cancer. J Steroid Biochem Mol Biol, 108: 179. Prostate Cancer 2008
350. Ma, C., Yoshioka, M., Boivin, A., Belleau, P., Gan, L., Takase, Y., Labrie, F., St-Amand, J. (2008) Erratum: Prostate specific genes and their regulation by dihydrotestosterone. Prostate, 68: 1372. Prostate Cancer 2008
349. Labrie, F. (2008) Comment to: Prostate specific antigen (PSA)-based screening. Int J Urol, 15: 757-762. Prostate Cancer 2008
348. Akaza, H., Labrie, F., Namiki, M. (2007) [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho. Jpn J Cancer Chemotherapy, 34: 657-669. Prostate Cancer 2007
347. Cantin, L., Faucher, F., Couture, J.F., de Jésus, K.P., Legrand, P., Ciobanu, L., Fréchette, Y., Labrecque, R., Singh, S.M., Labrie, F., Breton, R. (2007) Structural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally-designed steroidal ligand bearing a bulky chain directed toward helix 12. J Biol Chem, 282: 30910-9. Prostate Cancer 2007
346. Labrie, F. (2007) Multiple intracrine hormonal targets in the prostate: oportunities and challenges. BJU Int, 100: 48-51. Prostate Cancer 2007
345. Levesque, M.H., El-Alfy, M., Berger, L., Labrie, F., Labrie, C. (2007) Evaluation of AIbZIP and Cdc47 as Markers for Human Prostatic Diseases. Urology, 69: 196-201. Prostate Cancer 2007
344. Roy, J., Breton, R., Martel, C., Labrie, F., Poirier, D. (2007) Chemical synthesis and biological activities of 16α-derivatives of 5α-androstane-3α, 17 β-diol as antiandrogens. Bioorg Med Chem, 15: 3003-3018. Prostate Cancer 2007
343. Suzuki, K., Nishiyama, T., Hara, N., Yamana, K., Takahashi, K., Labrie, F. (2007) Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate Cancer Prostatic Dis., 10: 301-6. Prostate Cancer 2007
342. Swanson, C., Mellström, D., Lorentzon, M., Vanderput, L., Jakobsson, J., Rane, A., Karlsson, M., Ljunggren, O., Smith, U., Eriksson, A.E., Bélanger, A., Labrie, F., Ohlsson, C. (2007) The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab, 92: 4878-4882. Prostate Cancer 2007
341. Takase, Y., Luu-The, V., Poisson-Paré, D., Labrie, F., Pelletier, G. (2007) Expression of sulfotransferase 1E1 in human prostate as studied by in situ hybridization and immunocytochemistry. Prostate, 67: 405-409. Prostate Cancer 2007
340. Tenta, R., Katopodis, H., Chatzïioannou, A., Pilalis, E., Calvo, E., Luu-The, V., Labrie, F., Kolisis, F., Koutsilieris, M. (2007) Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics, 4: 309-18. Prostate Cancer 2007
339. Vandenput, L., Labrie, F., Mellström, D., Swanson, C., Knutsson, T., Peeker, R., Ljunggren, O., Orwoll, E., Eriksson, A.L., Johnell, O., Damber, J.E., Ohlsson, C. (2007) Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J. of Bone and Mineral Research: The Official Journal of the American Soc. for Bone and Mineral Research, 22: 220-7. Prostate Cancer 2007
338. Candas, B., Labrie, F., Gomez, J.L., Cusan, L., Chevrette, E., Levesque, J., Brousseau, G. (2006) Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol, 175: 510-517. Prostate Cancer 2006
337. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. Prostate Cancer 2006
336. Perreira De Jésus, K., Côté, P.L., Cantin, L., Blanchet, J., Labrie, F., Breton, R. (2006) Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Science: a publication of the Protein Society, 15: 987-99. Prostate Cancer 2006
335. Takase, Y., Lévesque, M.H., Luu-The, V., El-Alfy, M., Labrie, F., Pelletier, G. (2006) Expression of enzymes involved in estrogen metabolism in human prostate. J.Histochem Cytochem., 54: 911-21. Prostate Cancer 2006
334. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J., Candas, B. (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews, 26: 361-379. Prostate Cancer 2005
333. Labrie, F., Luu-The, V., Bélanger, A., Lin, S.-X., Simard, J., Pelletier, G., Labrie, C. (2005) Is DHEA a hormone? Starling Review. J Endocrinol, 187: 169-196. Prostate Cancer 2005
332. Labrie, F. (2004) Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Brazilian J Urol, 30: 3-12. Prostate Cancer 2004
331. Labrie, F. (2004) Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter, 20: 3-11. Prostate Cancer 2004
330. Labrie, F. (2004) Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl, 25: 305-313. Prostate Cancer 2004
329. Labrie, F. (2004) Status of androgen blockade in prostate cancer in 2003, in: Koutsilieris, M. et Labrie, F., eds: Prostate cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 157-170. Prostate Cancer 2004
328. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Bélanger, A., Brousseau, G., Lévesque, J. (2004) Screening decreases prostate cancer mortality: 11-year follow-up on the 1988 Quebec prospective randomized controlled trial. The Prostate, 59: 311-318. Prostate Cancer 2004
327. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Lévesque, J., Chevrette, E., Brousseau, G. (2004) Prostate Cancer Screening and Early Treatment: The Only Possibility for a Major Impact on Survival in Prostate Cancer, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 67-78. Prostate Cancer 2004
326. Labrie, F., Cusan, L., Gomez, J., Luu-The, V., Candas, B., Bélanger, A., Labrie, C. (2004) Major impact of hormonal therapy in localized prostate cancer - death can already be an exception. JSBMB, 92: 327-344. Prostate Cancer 2004
325. Qiu, W., Zhou, M., Labrie, F., Lin, S.-X. (2004) Crystal structures of the multi-specific 17β-hydroxysteroid dehydrogenase type 5: Critical androgen regulation in human peripheral tissues. Mol Endocrinol, 18: 1798-1807. Prostate Cancer 2004
324. Simard, J., Dumont, M., Soucy, P., Labrie, F., Tavtigian, S.V. (2004) Prostate Cancer Susceptibility Genes, in: Labrie, F. et Koutsilieris, M., eds: Prostate Cancer: Understanding the pathophysiology and re-designing a therapeutic approach, Athens, Greece, Paschalidis Medical Publications, pp 1-38. Prostate Cancer 2004
323. Labrie, F. (2003) Hormonal therapy in the management of prostate cancer at all stages of the disease, in: Syrigos, K.N., ed. Prostate Cancer: Biology, Diagnosis and Management, London, UK, Oxford University Press, pp 301-314. Prostate Cancer 2003
322. Labrie, F., Cusan, L., Gomez, J.L., Candas, B., Bélanger, A., Luu-The, V., Simard, J. (2003) De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception? Médecine/Sciences, 19: 910-19. Prostate Cancer 2003
321. Simard, J., Dumont, M., Labuda, D., Sinnett, D., Meloche, C., El Alfy, M., Berger, L., Lees, E., Labrie, F., Tavtigian, S.V. (2003) Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocrine Related Cancer, 10: 225-259. Prostate Cancer 2003
320. Labrie, F. (2002) Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198: 77-87. Prostate Cancer 2002
319. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. Prostate Cancer 2002
318. Labrie, F., Candas, B., Gomez, L.J., Cusan, L. (2002) Can combined androgen blockade provide long term control or possible cure of localized prostate cancer? Urology, 60: 115-119. Prostate Cancer 2002
317. Crawford, E.D., Miller, G., Labrie, F., Hirano, D., Batuello, J., Globe, M. (2001) Prostate cancer pathology, screening and epidemiology. Reviews in Urology, 3: S2-S10. Prostate Cancer 2001
316. Gomella, L.G., Labrie, F., Gamito, E.J., Brawer, M.K. (2001) Prostate cancer: risk assessment and diagnostic approaches. Reviews in Urology, 3: S31-S38. Prostate Cancer 2001
315. Labrie, F. (2001) Le cancer de la prostate: blocage combiné des androgènes comme traitement à tous les stades de la maladie. Oncologie, 3: 3-12. Prostate Cancer 2001
314. Labrie, F., Candas, B., Cusan, L., Gomez, J.L. (2001) The Laval University screening trial results (Chapter 17), in: Thompson, I.M., Resnick, M.I. et Klein, E.A., eds: Current Clinical Urology, Prostate Cancer Screening, Totowa, NJ, Humana Press Inc., pp 255-279. Prostate Cancer 2001
313. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. Prostate Cancer 2001
<< previous
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards